BTAI Quote, Financials, Valuation and Earnings

IGM Biosciences has a net margin of -6378.51% compared to BioXcel Therapeutics's net margin of -8894.9%. BioXcel Therapeutics's return on equity of -- beat IGM Biosciences's return on equity of -159.45%.

BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 1891.76%. On the other hand IGM Biosciences has an analysts' consensus of $1.88 which suggests that it could grow by 57.56%. Given that BioXcel Therapeutics has higher upside potential than IGM Biosciences, analysts believe BioXcel Therapeutics is more attractive than IGM Biosciences.

BioXcel Therapeutics has a beta of 0.640, which suggesting that the stock is 36.034% less volatile than S&P 500. In comparison IGM Biosciences has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.126%.

BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGM Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. IGM Biosciences pays out -- of its earnings as a dividend.

BioXcel Therapeutics quarterly revenues are $214K, which are smaller than IGM Biosciences quarterly revenues of $412K. BioXcel Therapeutics's net income of -$13.7M is higher than IGM Biosciences's net income of -$36.6M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while IGM Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 2.04x versus 26.88x for IGM Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Omeros has a net margin of -6378.51% compared to BioXcel Therapeutics's net margin of --. BioXcel Therapeutics's return on equity of -- beat Omeros's return on equity of --.

BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 1891.76%. On the other hand Omeros has an analysts' consensus of $36.00 which suggests that it could grow by 432.54%. Given that BioXcel Therapeutics has higher upside potential than Omeros, analysts believe BioXcel Therapeutics is more attractive than Omeros.

BioXcel Therapeutics has a beta of 0.640, which suggesting that the stock is 36.034% less volatile than S&P 500. In comparison Omeros has a beta of 2.352, suggesting its more volatile than the S&P 500 by 135.194%.

BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. Omeros pays out -- of its earnings as a dividend.

BioXcel Therapeutics quarterly revenues are $214K, which are larger than Omeros quarterly revenues of --. BioXcel Therapeutics's net income of -$13.7M is higher than Omeros's net income of -$32.2M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while Omeros's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 2.04x versus -- for Omeros. Usually stocks with elevated PS ratios are considered overvalued.

Organogenesis Holdings has a net margin of -6378.51% compared to BioXcel Therapeutics's net margin of 6.06%. BioXcel Therapeutics's return on equity of -- beat Organogenesis Holdings's return on equity of 0.29%.

BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 1891.76%. On the other hand Organogenesis Holdings has an analysts' consensus of $6.00 which suggests that it could grow by 41.18%. Given that BioXcel Therapeutics has higher upside potential than Organogenesis Holdings, analysts believe BioXcel Therapeutics is more attractive than Organogenesis Holdings.

BioXcel Therapeutics has a beta of 0.640, which suggesting that the stock is 36.034% less volatile than S&P 500. In comparison Organogenesis Holdings has a beta of 1.795, suggesting its more volatile than the S&P 500 by 79.497%.

BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Organogenesis Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. Organogenesis Holdings pays out -- of its earnings as a dividend.

BioXcel Therapeutics quarterly revenues are $214K, which are smaller than Organogenesis Holdings quarterly revenues of $126.7M. BioXcel Therapeutics's net income of -$13.7M is lower than Organogenesis Holdings's net income of $7.7M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while Organogenesis Holdings's PE ratio is 70.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 2.04x versus 1.16x for Organogenesis Holdings. Usually stocks with elevated PS ratios are considered overvalued.

scPharmaceuticals has a net margin of -6378.51% compared to BioXcel Therapeutics's net margin of -155.1%. BioXcel Therapeutics's return on equity of -- beat scPharmaceuticals's return on equity of -370.01%.

BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 1891.76%. On the other hand scPharmaceuticals has an analysts' consensus of $15.17 which suggests that it could grow by 494.77%. Given that BioXcel Therapeutics has higher upside potential than scPharmaceuticals, analysts believe BioXcel Therapeutics is more attractive than scPharmaceuticals.

BioXcel Therapeutics has a beta of 0.640, which suggesting that the stock is 36.034% less volatile than S&P 500. In comparison scPharmaceuticals has a beta of 0.380, suggesting its less volatile than the S&P 500 by 61.958%.

BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. scPharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. scPharmaceuticals pays out -- of its earnings as a dividend.

BioXcel Therapeutics quarterly revenues are $214K, which are smaller than scPharmaceuticals quarterly revenues of $12.2M. BioXcel Therapeutics's net income of -$13.7M is higher than scPharmaceuticals's net income of -$18.8M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while scPharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 2.04x versus 3.12x for scPharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.